The INIS Study. International Neonatal Immunotherapy Study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial

INIS Study Collaborative Group, Peter Brocklehurst, Sally Brearley, Khalid Haque, Andy Leslie, Alison Salt, Ben Stenson, Jim Stephenson, William Tarnow-Mordi, INIS Study Collaborative Group, Peter Brocklehurst, Sally Brearley, Khalid Haque, Andy Leslie, Alison Salt, Ben Stenson, Jim Stephenson, William Tarnow-Mordi

Abstract

Background: Sepsis is an important cause of neonatal death and perinatal brain damage, particularly in preterm infants. While effective antibiotic treatment is essential treatment for sepsis, resistance to antibiotics is increasing. Adjuvant therapies, such as intravenous immunoglobulin, therefore offer an important additional strategy. Three Cochrane systematic reviews of randomised controlled trials in nearly 6,000 patients suggest that non-specific, polyclonal intravenous immunoglobulin is safe and reduces sepsis by about 15% when used as prophylaxis but does not reduce mortality in this situation. When intravenous immunoglobulin is used in the acute treatment of neonatal sepsis, however, there is a suggestion that it may reduce mortality by 45%. However, the existing trials of treatment were small and lacked long-term follow-up data.This study will assess reliably whether treatment of neonatal sepsis with intravenous immunoglobulin reduces mortality and adverse neuro-developmental outcome.

Methods and design: A randomised, placebo controlled, double blind trial. Babies with suspected or proven neonatal sepsis will be randomised to receive intravenous immunoglobulin therapy or placebo.

Eligibility criteria: Babies must be receiving antibiotics and have proven or suspected serious infection AND have at least one of the following: birthweight less than 1500 g OR evidence of infection in blood culture, cerebrospinal fluid or usually sterile body fluid OR be receiving respiratory support via an endotracheal tube AND there is substantial uncertainty that intravenous immunoglobulin is indicated.

Exclusion criteria: Babies are excluded if intravenous immunoglobulin has already been given OR intravenous immunoglobulin is thought to be needed OR contra-indicated. Trial treatment: Babies will be given either 10 ml/kg of intravenous immunoglobulin or identical placebo solution over 4-6 hours, repeated 48 hours later.

Primary outcome: Mortality or major disability at two years, corrected for gestational age.

Data collection: Data will be collected at discharge from hospital and at 2 years of age (corrected for gestation) using a parental questionnaire and a health status questionnaire completed during a face-to-face follow-up appointment with the child's paediatrician.

Trial registration: Current Controlled Trials ISCRTN94984750.

References

    1. Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth weight. JAMA. 1997;278:207–11. doi: 10.1001/jama.278.3.207.
    1. Murphy DJ, Sellers S, MacKenzie IZ, Yudkin PL, Johnson AM. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet. 1995;346:1449–54. doi: 10.1016/S0140-6736(95)92471-X.
    1. Parliamentary Select Committee House of Lords inquiry into antimicrobial resistance. Commun Dis Rep CDR Wkly. 1998;8:147–150.
    1. Levy SB. The challenge of antibiotic resistance. Sci Am. 1998;278:46–53.
    1. Isaacs D, Barfield CP, Grimwood K, McPhee AJ, Minutillo C, Tudehope DI. Systemic bacterial and fungal infections in infants in Australian neonatal units. Australian Study Group for Neonatal Infections. Med J Aust. 1995;162:198–201.
    1. UK Neonatal Staffing study group Patient volume, staffing and workload in relation to risk-adjusted outcomes in a stratified sample of UK neonatal intensive care units: a prospective evaluation. Lancet. 2002;359:99–107. doi: 10.1016/S0140-6736(02)07366-X.
    1. Fanaroff AA, Korones SB, Wright LL, Verter J, Poland RL, Bauer CR, Tyson JE, Philips JB, Edwards W, Lucey JF, Catz CS, Shankaran S, Oh W. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr Infect Dis J. 1998;17:593–8. doi: 10.1097/00006454-199807000-00004.
    1. Schelonka RL, Chai MK, Yoder BA, Hensley D, Brockett RM, Ascher DP. Volume of blood required to detect common neonatal pathogens. J Pediatr. 1996;129:275–8. doi: 10.1016/S0022-3476(96)70254-8.
    1. Barton L, Hodgman JE, Pavlova Z. Causes of death in the extremely low birth weight infant. Pediatrics. 1999;103:446–51. doi: 10.1542/peds.103.2.446.
    1. Nelson KB, Dambrosia JM, Grether JK, Phillips TM. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol. 1998;44:665–75. doi: 10.1002/ana.410440413.
    1. Dammann O, Leviton A. Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant. Semin Pediatr Neurol. 1998;5:190–201. doi: 10.1016/S1071-9091(98)80034-X.
    1. Dammann O, Leviton A. Brain damage in preterm newborns: Might enhancement of developmentally regulated endogenous protection open a door for prevention? Pediatrics. 1999;104:541–50. doi: 10.1542/peds.104.3.541.
    1. Baley JE. Neonatal sepsis: the potential for immunotherapy. Clin Perinatol. 1988;15:755–71.
    1. Fujiwara T, Taniuchi S, Hattori K, Kobayashi T, Kinoshita Y, Kobayashi Y. Effect of immunoglobulin therapy on phagocytosis by polymorphonuclear leucocytes in whole blood of neonates. Clin Exp Immunol. 1997;107:435–9. doi: 10.1046/j.1365-2249.1997.d01-957.x.
    1. Christensen RD, Brown MS, Hall DC, Lassiter HA, Hill HR. Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis. J Pediatr. 1991;118:606–14.
    1. Harper TE, Christensen RD, Rothstein G, Hill HR. Effect of intravenous immunoglobulin G on neutrophil kinetics during experimental group B streptococcal infection in neonatal rats. Rev Infect Dis. 1986;8:S401–8.
    1. Masouye P, Gunning K, Pittet JF, Suter PM, Morel DR. Xanthine derivative HWA 138 attenuates hemodynamic and oxygen uptake dysfunction secondary to severe endotoxin shock in sheep. Circ Shock. 1992;36:113–19.
    1. Lundblad R, Ekstrom P, Giercksky KE. Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock. 1995;3:210–15. doi: 10.1097/00024382-199503000-00009.
    1. Zeni F, Pain P, Vindimian M, Gay JP, Gery P, Bertrand M, Page Y, Page D, Bertrand JC. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med. 1996;24:207–14. doi: 10.1097/00003246-199602000-00005.
    1. Staudinger T, Presterl E, Graninger W, Locker GJ, Knapp S, Laczika K, Klappacher G, Stoiser B, Wagner A, Tesinsky P, Kordova H, Frass M. Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Intensive Care Med. 1996;22:888–93. doi: 10.1007/BF02044112.
    1. Lauterbach R, Zembala M. Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Pediatr. 1996;155:404–9. doi: 10.1007/BF01955273.
    1. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med. 1999;27:807–14. doi: 10.1097/00003246-199904000-00042.
    1. Perez EM, Weisman LE. Novel approaches to the prevention and therapy of neonatal bacterial sepsis. Clin Perinatol. 1997;24:213–29.
    1. Gillan ER, Christensen RD, Suen Y, Ellis R, Ven C van de, Cairo MS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood. 1994;84:1427–33.
    1. Drossou-Agakidou V, Kanakoudi-Tsakalidou F, Sarafidis K, Taparkou A, Tzimouli V, Tsandali H, Kremenopoulos G. Administration of recombinant human granulocyte colony-stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial. Eur J Pediatr. 1998;157:583–8. doi: 10.1007/s004310050884.
    1. Schibler KR, Osborne KA, Leung LY, Le TV, Baker SI, Thompson DD. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics. 1998;102:6–13. doi: 10.1542/peds.102.1.6.
    1. Bedford Russell A, Emmerson A, Wilkinson N, Holland B, Sweet D, Davies E. UK multicentre prospective, randomised double blind placebo controlled trial of rhG-CSF (granulocyte colony-stimulating factor) in neonatal sepsis. Proceedings of the Royal College of Paediatrics and Child Health Spring meeting. 1999. p. G69.
    1. Carr R, Modi N, Doré J, El-Rifai R, Lindo Dl. A randomized, controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newborns less than 32 weeks gestation. Pediatrics. 1999;103:796–802. doi: 10.1542/peds.103.4.796.
    1. Cairo MS, Agosti J, Ellis R, Laver JJ, Puppala B, deLemos R, Givner L, Nesin M, Wheeler JG, Seth T, Ven C van de, Fanaroff A. A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates. J Pediatr. 1999;134:64–70. doi: 10.1016/S0022-3476(99)70373-2.
    1. Tarnow-Mordi W, Healy M. Distinguishing between "no evidence of effect" and "evidence of no effect" in randomised controlled trials and other comparisons. Arch Dis Child. 1999;80:210–13.
    1. Cairo MS, Worcester CC, Rucker RW, Hanten S, Amlie RN, Sender L, Hicks DA. Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy for neonatal neutropenia and sepsis. J Pediatr. 1992;120:281–5.
    1. Tollner U, Pohlandt F, Heinze F, Henrichs I. Treatment of septicaemia in the newborn infant: choice of initial antimicrobial drugs and the role of exchange transfusion. Acta Paediatr Scand. 1977;66:605–10. doi: 10.1111/j.1651-2227.1977.tb07955.x.
    1. Northern Neonatal Network Nursing Initiative Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: outcome at 2 years. Northern Neonatal Nursing Initiative Trial Group. Lancet. 1996;348:229–32. doi: 10.1016/S0140-6736(95)12506-X.
    1. Ohlsson A, Lacy JB. The Cochrane Libary. Oxford: Update Software; 2003. Intravenous immunoglobulin for preventing infection in preterm and/or low-birthweight infants (Cochrane Review)
    1. Ohlsson A, Lacy JB. The Cochrane Libary. Oxford: Update Software; 2003. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates (Cochrane Review)
    1. Samatha S, Jalalu MP, Hegde RK, Vishwanath D, Maiya PP. Role of IgM enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatr J. 1997;11:1–6.
    1. Shenoi A, Nagesh NK, Maiya PP, Bhat SR, Rao SDS. Multicentre randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatr. 1999;36:1113–18.
    1. Mancila Ramirez J, Gonzales R, Castellanos C, Garcia P, Santos JI. Immunoglobulina intravenosa en el tratamiento de septicemia neonatal. Bol Med Hosp Infant Mex. 1992;49:4–11.
    1. Weisman LE, Stoll B, Kueser T, Rubio TT, Frank CG, Heiman HS, Subramanian KN, Hankins CT, Anthony BF, Cruess DF. Intravenous immune globulin therapy for early-onset sepsis in premature neonates. J Pediatr. 1992;121:434–43. doi: 10.1016/S0022-3476(05)81802-5.
    1. Chen JY. Intravenous immunoglobulin in the treatment of full-term and premature newborns with sepsis. J Formosa Med Assoc. 1996;95:839–44.
    1. Haque KN, Zaidi MH, Bahakim H. IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. Am J Dis Child. 1988;142:1293–6.
    1. Erdem G, Yurdakok M, Tekinalp G, Ersoy F. The use of IgM-enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. Turk J Pediatr. 1993;35:277–81.
    1. Sidiropoulos D, Boehme U, von Muralt G, Morell A, Barandun S. Immunoglobulin supplementation in prevention or treatment of neonatal sepsis. Pediatr Infect Dis. 1986;5:S193–4.
    1. Jenson HB, Pollock BH. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics. 1997;99:E2. doi: 10.1542/peds.99.2.e2.
    1. Alejandria MM, Lansang MA, Dans LF, Mantaring JBV. The Cochrane Libary. Oxford: Update Software; 2003. Intravenous immunoglobulin for treating sepsis and shock (Cochrane Review)
    1. Turner ML, Ironside JW. New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. Blood Rev. 1998;12:255–68. doi: 10.1016/S0268-960X(98)90007-8.
    1. Turner M. The impact of new variant Creutzfeldt-Jakob disease on blood transfusion practice. Br J Haematol. 1999;106:842–50. doi: 10.1046/j.1365-2141.1999.01457.x.
    1. Foster PR. Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med. 1999;9:3–14. doi: 10.1046/j.1365-3148.1999.009001003.x.
    1. Osborn DA, Lui K, Pussell P, Jana AK, Desai AS, Cole M. T and Tk antigen activation in necrotising enterocolitis: manifestations, severity of illness, and effectiveness of testing. Arch Dis Child Fetal Neonatal Ed. 1999;80:F192–F197.
    1. Mollison P, Engelfriet C, Contreras M. Blood Transfusion in Clinical Medicine. 10. Oxford: Blackwell; 1997.
    1. Haque KN, Remo C, Bahakim H. Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin Exp Immunol. 1995;101:328–33.
    1. Haque K. Management of neonatal sepsis in the UK: a national audit of practice. J of Clinical Excellence. 2000;2:81–85.
    1. Taylor D, Kenyon S, Peto R, Tarnow-Mordi W. Preterm premature rupture of membranes. Lancet. 1996;347:204. doi: 10.1016/S0140-6736(96)90391-8.
    1. Taylor D, Kenyon S, Tarnow-Mordi W. Infection and preterm labour [comment] Br J Obstet Gynaecol. 1997;104:1338–40.
    1. Tarnow-Mordi W. Consent, information, and neonatal research [letter] Lancet. 1999;353:1530–1. doi: 10.1016/S0140-6736(05)67227-3.
    1. Johnson A. Follow up studies: a case for a standard minimum data set. Arch Dis Child Fetal Neonatal Ed. 1997;76:F61–F63.
    1. A report of two working groups convened by the National Perinatal Epidemiology Unit and the former Oxford Regional Health Authority. Oxford: NPEU; 1994. Disability and perinatal care: measurement of health status at two years.
    1. Saudino KJ, Dale PS, Oliver B, Petrill SA, Richardson V, Rutter M, Simonoff E, Stevenson J, Plomin R. The validity of parent-based assessment of the cognitive abilities of two-year olds. British Journal of Development Psychology. 1198;16:349–63.
    1. Bayley N. Bayley Scales of Infant Development. 2. San Antonio TX Psychological Corporation; 1993.
    1. Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S, Mantel N, McPherson K, Peto J, Smith DG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. 1. Introduction and design. Br J Cancer. 1976;34:585–612.
    1. Tucker J, Tarnow-Mordi W, Gould C, Parry G, Marlow N. UK neonatal intensive care services in 1996. Arch Dis Child Fetal Neonatal Ed. 1999;80:F233–F234.
    1. Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ. 1998;317:1170–1.
    1. Early versus delayed neonatal administration of a synthetic surfactant – the judgment of OSIRIS. The OSIRIS (open study of infants at high risk of or with respiratory insufficiency – the role of surfactant) Collaborative Group. Lancet. 1992;340:1363–9. doi: 10.1016/0140-6736(92)92557-V.
    1. Human Immunoglobulin for Intravenous Administration. Information Pamphlet, Scottish National Blood Transfusion Service; 2000.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다